This is a Validated Antibody Database (VAD) review about
human ULBP3, based on 8 published articles (
read how Labome selects the articles), using ULBP3 antibody in all methods. It is aimed to help Labome visitors find the most suited ULBP3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
ULBP3 synonym: N2DL-3; NKG2DL3; RAET1N
others
| | - flow cytometry; human; loading ...; fig 3
| ULBP3 antibody (R&D, FAB1517P) was used in flow cytometry on human samples (fig 3). Stem Cell Reports (2020) ncbi |
| | - flow cytometry; human; loading ...; fig s2e
| ULBP3 antibody (R&D System, 166510) was used in flow cytometry on human samples (fig s2e). Cell Death Dis (2019) ncbi |
R&D Systems
| mouse monoclonal (166510) | - flow cytometry; human; loading ...; fig 4d
| R&D Systems ULBP3 antibody (Biotechne, 166,510) was used in flow cytometry on human samples (fig 4d). Oncoimmunology (2022) ncbi |
| mouse monoclonal (166514) | - flow cytometry; human; loading ...; fig 1f
| R&D Systems ULBP3 antibody (R&D Systems, 166514) was used in flow cytometry on human samples (fig 1f). J Virol (2018) ncbi |
| domestic goat polyclonal | - flow cytometry; human; loading ...; fig 1
| R&D Systems ULBP3 antibody (R&D systems, AF1517) was used in flow cytometry on human samples (fig 1). PLoS Pathog (2016) ncbi |
| domestic goat polyclonal | - flow cytometry; human; fig s1
| R&D Systems ULBP3 antibody (R&D systems, 1517) was used in flow cytometry on human samples (fig s1). Oncotarget (2016) ncbi |
Santa Cruz Biotechnology
| mouse monoclonal (D-1) | - western blot; human; 1:300; loading ...; fig 5b
| Santa Cruz Biotechnology ULBP3 antibody (Santa cruz, sc-390844) was used in western blot on human samples at 1:300 (fig 5b). Cancer Cell Int (2017) ncbi |
Novus Biologicals
| domestic rabbit polyclonal | - immunohistochemistry - frozen section; human; 1:500; loading ...; fig 1g
| In order to investigate the role of natural killer cells to lymphangioleiomyomatosis pathogenesis, Novus Biologicals ULBP3 antibody (Novus, NBP2-31866) was used in immunohistochemistry - frozen section on human samples at 1:500 (fig 1g). JCI Insight (2016) ncbi |
Secchiari F, Nu xf1 ez S, Sierra J, Ziblat A, Regge M, Raffo Iraolagoitia X,
et al. The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology. Oncoimmunology. 2022;11:2104991
pubmed publisher Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A,
et al. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020;14:49-59
pubmed publisher Chollat Namy M, Ben Safta Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J. The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10:695
pubmed publisher Dassa L, Seidel E, Oiknine Djian E, Yamin R, Wolf D, Le Trilling V,
et al. The Human Cytomegalovirus Protein UL148A Downregulates the NK Cell-Activating Ligand MICA To Avoid NK Cell Attack. J Virol. 2018;92:
pubmed publisher Oh S, Yang J, Kim O, Ahn E, Kang W, Lee J,
et al. Human U87 glioblastoma cells with stemness features display enhanced sensitivity to natural killer cell cytotoxicity through altered expression of NKG2D ligand. Cancer Cell Int. 2017;17:22
pubmed publisher Osterburg A, Nelson R, Yaniv B, Foot R, Donica W, Nashu M,
et al. NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline. JCI Insight. 2016;1:e87270
pubmed publisher Sturgill E, Malouli D, Hansen S, Burwitz B, Seo S, Schneider C,
et al. Natural Killer Cell Evasion Is Essential for Infection by Rhesus Cytomegalovirus. PLoS Pathog. 2016;12:e1005868
pubmed publisher Bauman Y, Drayman N, Ben nun Shaul O, Vitenstein A, Yamin R, Ophir Y,
et al. Downregulation of the stress-induced ligand ULBP1 following SV40 infection confers viral evasion from NK cell cytotoxicity. Oncotarget. 2016;7:15369-81
pubmed publisher
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
